Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JT001 (VV116) vs Favipiravir in Moderate to Severe COVID-19
NCT05279235Phase 3Terminated
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of deuremidevir in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Vinnerna Biosciences Co., Ltd.. Started Mar 2022; status: terminated.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05279235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279235.